Skip to main content
. 2019 Oct 14;10(10):784. doi: 10.1038/s41419-019-2023-1

Table 4.

miR-3163 enhanced the antitumor effect of sorafenib on cultured HCC cells’ surviving

PDCs Groups Sorafenib Regorafenib Lenvatinib Anlotinib Apatinib
IC50 values (μmol/L) of molecular targeting agents on cultured HCC cells’ surviving
No. 1 Control 1.46 ± 0.10 1.60 ± 0.16 0.73 ± 0.41 1.83 ± 0.33 1.98 ± 0.86
miR-3163 0.33 ± 0.11 0.61 ± 0.08 0.12 ± 0.02 0.40 ± 0.14 0.99 ± 0.63
miR-3163 + ADAM-17Mut 1.55 ± 0.08 1.58 ± 0.52 0.67 ± 0.20 1.55 ± 0.58 1.91 ± 0.11
No. 2 Control 1.51 ± 0.52 1.68 ± 0.45 0.36 ± 0.11 1.65 ± 0.59 1.59 ± 0.29
miR-3163 0.28 ± 0.05 0.57 ± 0.24 0.07 ± 0.01 0.52 ± 0.08 0.54 ± 0.07
miR-3163 + ADAM-17Mut 1.44 ± 0.85 1.86 ± 0.34 0.33 ± 0.04 1.48 ± 0.62 1.74 ± 0.43
No. 3 Control 1.24 ± 0.38 1.61 ± 0.09 0.85 ± 0.07 3.81 ± 0.53 0.99 ± 0.16
miR-3163 0.68 ± 0.45 0.48 ± 0.06 0.22 ± 0.13 1.62 ± 0.44 0.23 ± 0.06
miR-3163 + ADAM-17Mut 1.35 ± 0.26 1.40 ± 0.11 0.74 ± 0.20 2.84 ± 0.74 0.75 ± 0.15
No. 4 Control 2.39 ± 0.44 1.96 ± 0.33 1.10 ± 0.33 2.73 ± 0.98 2.16 ± 0.44
miR-3163 0.98 ± 0.19 0.22 ± 0.04 0.58 ± 0.09 0.87 ± 0.30 0.90 ± 0.54
miR-3163 + ADAM-17Mut 1.88 ± 0.69 1.63 ± 0.30 1.36 ± 0.68 2.07 ± 0.36 1.93 ± 0.84
No. 5 Control 3.10 ± 0.46 2.62 ± 0.64 1.66 ± 0.40 2.81 ± 0.10 2.74 ± 0.71
miR-3163 1.27 ± 0.51 0.79 ± 0.28 0.40 ± 0.07 0.98 ± 0.56 1.22 ± 0.28
miR-3163 + ADAM-17Mut 3.06 ± 0.47 1.70 ± 0.53 1.47 ± 0.88 1.44 ± 0.47 2.53 ± 0.21

PDCs patients-derived HCC cell lines